COGT vs. ARCT, PRTC, SIGA, AUPH, YMAB, IRON, SVRA, WVE, DNTH, and MLYS
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Arcturus Therapeutics (ARCT), PureTech Health (PRTC), SIGA Technologies (SIGA), Aurinia Pharmaceuticals (AUPH), Y-mAbs Therapeutics (YMAB), Disc Medicine (IRON), Savara (SVRA), Wave Life Sciences (WVE), Dianthus Therapeutics (DNTH), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical preparations" industry.
Cogent Biosciences (NASDAQ:COGT) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.
Arcturus Therapeutics has higher revenue and earnings than Cogent Biosciences. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cogent Biosciences had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 10 mentions for Cogent Biosciences and 9 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.67 beat Cogent Biosciences' score of -0.05 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.
94.5% of Arcturus Therapeutics shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by insiders. Comparatively, 13.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Arcturus Therapeutics received 153 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.80% of users gave Cogent Biosciences an outperform vote while only 65.39% of users gave Arcturus Therapeutics an outperform vote.
Cogent Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -81.59%. Arcturus Therapeutics' return on equity of -37.61% beat Cogent Biosciences' return on equity.
Cogent Biosciences presently has a consensus target price of $14.67, indicating a potential upside of 97.13%. Arcturus Therapeutics has a consensus target price of $64.86, indicating a potential upside of 117.79%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than Cogent Biosciences.
Cogent Biosciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500.
Summary
Arcturus Therapeutics beats Cogent Biosciences on 12 of the 17 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
